(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of 12.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Editas Medicine's revenue in 2024 is $69,407,000.On average, 9 Wall Street analysts forecast EDIT's revenue for 2024 to be $2,788,031,795, with the lowest EDIT revenue forecast at $90,461,771, and the highest EDIT revenue forecast at $4,827,369,074. On average, 7 Wall Street analysts forecast EDIT's revenue for 2025 to be $2,199,536,853, with the lowest EDIT revenue forecast at $1,644,759,480, and the highest EDIT revenue forecast at $2,604,229,923.
In 2026, EDIT is forecast to generate $10,067,901,729 in revenue, with the lowest revenue forecast at $3,836,401,487 and the highest revenue forecast at $19,904,056,847.